Influence of the dissolution medium on the release of dehydroepiandrosterone from lipophilic suppositories
References
- 1. Azarmi S. et al.: Current perspectives in dissolution testing of conventional and novel dosage forms. Int. J. Pharm., 328(1), 12, 2007.
- 2. Babar A., Fares H. M., Plakogiannis F. M.: In vitro release of testosterone from suppository bases and in vivo absorption studies in human males. J. Pharm. Sci., 82(4), 389, 1993.
- 3. Beral V., Bull D., Reeves G.: Endometrial cancer and hormonereplacement therapy in the Million Women Study. Lancet, 365, 1543, 2005.
- 4. Bergogne-Bérézin E., Bryskier A.: The suppository form of antibiotic administration: pharmacokinetics and clinical application.J. Antimicrob. Chemother., 43(2), 177, 1999.
- 5. Buster J.E., Casson P.R. (2000). Biology and use in therapeutic intervention. in Menopause: Biology and Pathobiology. Lobo R. A., Kelsey J. and Marcus R. (editors). San Diego: Academic Press; p 628.
- 6. Casson P. R. et al.: Dehydroepiandrosterone (DHEA) replacement in postmenopausal women: Present status and future promise.Menopause, 4, 225, 1997.
- 7. Casson P. R. et al.: Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am.J. Obstet. Gynecol., 169, 1536, 1993.
- 8. Casson P. R. et al.: Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril, 63(5), 1027, 1995.
- 9. Castelo-Branco C. et al.: Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas, 52(Suppl. 1), 46, 2005.
- 10. Chicco D. et al.: Correlation of in vitro and in vivo paracetamol availability from layered excipient suppositories. Int. J. Pharm., 189, 147, 1999.
- 11. Czarnecki W., Kasperek R.: Patent RP Nr P337979 z 21.01.2000r.Biomed Wytwórnia Surowic i Szczepionek w Lublinie.
- 12. Dal Zorro M. et al.: Effect of the surfactant on the availability of piroxicam as a poorly hydrosoluble drug from suppositories.Pharmazie, 67(1), 37, 2012.
- 13. Ghorab D., Refai H., Tag R.: Preparation and evaluation of fenoterol hydrobromide suppositories. Drug Discov. Ther., 5(6), 311, 2011.
- 14. Hargoli S. et al.: Preparation and In vitro Evaluation of Naproxen Suppositories. Indian J. Pharm. Sci., 75(2), 143, 2013.
- 15. Kalmár É. et al.: Novel sample preparation method for surfactant containing suppositories: effect of micelle formation on drug recovery. J. Pharm. Biomed. Anal., 83, 149, 2013.
- 16. Karavana S. Y. et al.: Dissolution and histological studies on ordidazole vaginal formulation. Acta Pharma. Sci., 52, 430, 2010.
- 17. Labrie F. et al.: Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause, 16(5), 923, 2009.
- 18. Labrie F. et al.: Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric, 14(2), 282, 2011.
- 19. Labrie F. et al.: Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.Menopause, 16(5), 907, 2009.
- 20. Labrie F. et al.: Is Dehydroepiandrosterone a hormone? J. Endocrinol., 187,169, 2005.
- 21. Labrie F. et al.: Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab., 82, 2396, 1997.
- 22. Lynch C.: Vaginal estrogen therapy for the treatment of atrophic vaginitis. J. Womens Health (Larchmt), 18(10), 1595, 2009.
- 23. Nestler J. E. et al.: Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J. Clin. Endocrinol. Metab., 66, 57, 1988.
- 24. Niraj et al.: Effect of Adjuvants on the Release Pattern of Suppositories Containing Paracetamol. RJCES, 1(1), 19, 2013.
- 25. Odeniyi M. A., Jaiyeoba K. T.: Effects of interacting variables on the release properties of chloroquine and aminophylline suppositories.Trop. J. Pharm. Res., 3(1), 285, 2004.
- 26. Panjari M., Davis S.R.: DHEA for postmenopausal women: a review of the evidence. Maturitas, 66(2), 172, 2010.
- 27. Panjari M., Davis S.R.: Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas, 70(1), 22, 2011.
- 28. Polish Pharmacopoeia IXth ed., vol. I, PTF Warsaw (2011).
- 29. Realdon N. et al.: Effects of surfactant characteristics on drug availability from suppositories. Pharmazie, 63(6), 459, 2008.
- 30. Sah M. L., Saini T.R.: Formulation development and release studies of indomethacin suppositories. Indian J. Pharm. Sci., 70(4), 498, 2008.
- 31. Varshney H. M., Chatterjee A.: Formulation, evaluation and in-vitro release characteristics of zaltoprofen suppositories. Asian J. Pharm.Clin. Res., 5(4), 235, 2012.
- 32. Varshney H. M., Tanwar Y. S.: Effect of different surfactants on the release pattern of cocoa butter suppositories containing flurbiprofen sodium. Acta Pharm. Sci., 52, 129, 2010.
- 33. Verma P. et al.: Routes of drug administration. Int. J. Pharm. Studies Res., 1(1), 54, 2010.
Language: English
Page range: 46 - 50
Submitted on: Feb 18, 2014
Accepted on: Mar 4, 2014
Published online: May 30, 2014
Published in print: Jun 1, 2014
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2014 Regina Kasperek1, Krzysztof Galczynski, Magdalena Nalesniak, Karol Iwaniak, Ewa Poleszak, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.